Prosecution Insights
Last updated: May 29, 2026

Examiner: KIM, YOUNG J

Tech Center 3600 • Art Units: 1637 1681 3619

This examiner grants 65% of resolved cases

Performance Statistics

64.8%
Allow Rate
+12.8% vs TC avg
1,165
Total Applications
+17.9%
Interview Lift
1159
Avg Prosecution Days
Based on 1107 resolved cases, 2023–2026

Rejection Statute Breakdown

4.2%
§101 Eligibility
6.0%
§102 Novelty
61.4%
§103 Obviousness
7.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18565027 POLYNUCLEOTIDE SEQUENCING USING IONOPHORES Non-Final OA Illumina, Inc.
19336117 Single Cell Nucleic Acid Detection and Analysis Final Rejection President and Fellows of Harvard College
18452628 MARKER AND METHOD FOR ANALYSING BIOLOGICAL SAMPLES Non-Final OA LEICA MICROSYSTEMS CMS GMBH
18283896 A primer-probe composition and a kit for detecting EGFR gene mutations Non-Final OA BOE TECHNOLOGY GROUP CO., LTD.
17879871 Ultraspecific Nucleic Acid Sensors for Low-Cost Liquid Biopsies Final Rejection ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
17611788 RAPID ANEUPLOIDY DETECTION Non-Final OA The Johns Hopkins University
17956596 METHODS AND KITS FOR IDENTIFYING, DIAGNOSING AND TREATING PROSTATE CARCINOMAS Final Rejection 10x Genomics, Inc.
15996236 MICROFLUIDIC DEVICES Final Rejection Bio-Rad Laboratories, Inc.
18580422 COMPOSITIONS AND METHODS FOR DETECTION OF LIVER CANCER Non-Final OA MERCY BIOANALYTICS, INC.
18173097 ALL-IN-ONE LUMINESCENCE-BASED POINT-OF-CARE TESTING DEVICE FOR VIRUS DIAGNOSIS Non-Final OA The Hong Kong Polytechnic University
17985485 SYSTEMS AND METHODS FOR GENERATION OF EMULSIONS WITH SUITABLE CLARITY WITH APPLICATIONS OF USE Final Rejection Enumerix, Inc.
18279714 TUMOR CELL IDENTIFICATION BY MAPPING MUTATIONS IN BULK DNA SEQUENCES TO SINGLE CELL RNA SEQUENCES Non-Final OA AMAZON TECHNOLOGIES, INC.
17924018 COMPOSITION FOR NUCLEIC ACID ANALYSIS, NUCLEIC ACID ANALYZING METHOD, AND NUCLEIC ACID ANALYZER Non-Final OA HITACHI HIGH-TECH CORPORATION
18503936 Highly Sensitive EGFRvIII Detection Non-Final OA The General Hospital Corporation
18468298 COMPOSITIONS AND METHODS FOR CHARACTERIZING LYMPHOMA AND RELATED CONDITIONS Non-Final OA The General Hospital Corporation
18042265 KIT AND METHOD FOR ISOTHERMAL RAPID DETECTION OF SARS-COV-2 VIRUS NUCLEIC ACID Non-Final OA SHANGHAI JIAO TONG UNIVERSITY
17677713 ON-CHIP OPTICAL REAL-TIME DNA SEQUENCING Final Rejection Seagate Technology LLC
18631561 MICROFLUIDIC SYSTEM FOR AMPLIFYING AND DETECTING POLYNUCLEOTIDES IN PARALLEL Final Rejection Handylab, Inc.
18889834 DETECTING POLYNUCLEOTIDES WITH BARCODED OLIGONUCLEOTIDE PROBES Final Rejection Singular Genomics Systems, Inc.
18537266 CONTROLLED ROLLING CIRCLE AMPLIFICATION Non-Final OA Singular Genomics Systems, Inc.
18157434 Methods and Compositions for Detecting Virulent and Avirulent Escherichia coli Strains Final Rejection The Florida State University Research Foundation, Inc.
18303700 MICROFLUIDIC DEVICES AND OBSERVATION METHODS Non-Final OA TOPPAN Inc.
17015829 Smartphone PCR Device Final Rejection Roche Molecular Systems, Inc.
18419885 DNA-Antigen Exchange and Amplification Final Rejection Ultivue, Inc.
18580232 USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE RISK OF COMPLICATIONS IN A PATIENT ADMITTED TO A HEALTHCARE FACILITY Non-Final OA BIOASTER
18261995 NON-INVASIVE CANCER DETECTION BASED ON DNA METHYLATION CHANGES Non-Final OA NUCLEIX LTD.
18478492 DETECTING CRONOBACTER WITH HELICASE-DEPENDENT AMPLIFICATION ASSAY Non-Final OA Neogen Corporation
18552414 MOLECULAR SUBTYPING OF COLORECTAL LIVER METASTASES TO PERSONALIZE TREATMENT APPROACHES Non-Final OA Endeavor Health Clinical Operations
18336352 SAMPLE PREPARATION, PROCESSING AND ANALYSIS SYSTEMS Non-Final OA IntegenX, Inc.
18036439 METHOD Non-Final OA ULIFETEC SAS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month